首页> 外文期刊>Clinical pulmonary medicine >Treatment of Mycobacterium avium Complex Lung Disease With Clofazimine
【24h】

Treatment of Mycobacterium avium Complex Lung Disease With Clofazimine

机译:用氯富咪胺治疗分枝杆菌

获取原文
获取原文并翻译 | 示例
           

摘要

Synopsis: Mycobacterium avium and Mycobacterium intracellulare, collectively known as the M. avium complex, are the most common causes of nontuberculous mycobaterial lung disease. Treatment of M. avium complex lung disease is challenging, as it requires patients to adhere to a multidrag regimen that is notorious for adverse drug effects. In this retrospective study by Jarand et al, clofazimine-containing regimens exhibited higher sputum conversion rates than rifampin-containing regimens. Rates of microbiologic relapse and retreatment were similar between the 2 groups. Source: Jarand J, Davis JP, Cowie RL, et al. Long-term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and/or rifampin." Chest. 2016; 149(5): 1285-293.
机译:概要:分枝杆菌和分枝杆菌,元素群,统称为鸟杆菌络合物,是最常见的无结核分枝杆菌肺疾病的原因。 治疗鸟杆菌复合物肺部疾病的治疗具有挑战性,因为它要求患者遵守对不良药物影响的多种剂量方案。 在Jarand等人的这项回顾性研究中,含氯氟齐胺的方案比含利福平的方案表现出更高的痰液转化率。 两组之间的微生物复发和撤退率相似。 资料来源:Jarand J,Davis JP,Cowie RL等。 在包括氯富咪胺和/或利福平在内的治疗治疗的患者中,鸟分枝杆菌复合肺疾病的长期随访。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号